PCM
VNDA icon

Piermont Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Piermont Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,820
Closed -$206K – 211
2018
Q2 		$206K Sell
10,820
-1,910
-15% -$31.9K 0.06% 230
2018
Q1 		$215K Sell
12,730
-2,020
-14% -$33.8K 0.07% 230
2017
Q4 		$224K Sell
14,750
-810
-5% -$12K 0.07% 228
2017
Q3 		$279K Sell
15,560
-16,600
-52% -$278K 0.09% 223
2017
Q2 		$524K Sell
32,160
-5,640
-15% -$81.3K 0.15% 225
2017
Q1 		$529K Hold
37,800
– – 0.13% 226
2016
Q4 		$603K Sell
37,800
-740
-2% -$11.9K 0.14% 214
2016
Q3 		$641K Buy
+38,540
New +$519K 0.15% 208

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Piermont Capital Management's VNDA Position: Q3 2018 in Review

Piermont Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 10,820 shares — an estimated $206K sold.

Piermont Capital Management first reported a position in VNDA in Q3 2016 and held it in 8 quarters. The position peaked at $641K in Q3 2016. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

  • Piermont Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 10,820 Vanda Pharmaceuticals shares in Q3 2018, an estimated $206K.
  • Piermont Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2016 and held it in 8 quarters.
  • Piermont Capital Management's Vanda Pharmaceuticals position peaked at $641K in Q3 2016.
  • 160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.